Literature DB >> 23322522

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.

Chikako Suzuki1, Lennart Blomqvist, Thomas Hatschek, Lena Carlsson, Zakaria Einbeigi, Barbro Linderholm, Birgitta Lindh, Niklas Loman, Martin Malmberg, Samuel Rotstein, Martin Söderberg, Marie Sundqvist, Thomas M Walz, Gunnar Aström, Hirofumi Fujii, Hans Jacobsson, Bengt Glimelius.   

Abstract

The aim of this was to determine whether the change of size observed at the first response evaluation after initiation of first-line combination chemotherapy correlates with overall survival (OS) in patients with metastatic breast cancer (MBC). The change in size of tumors derived from measurements according to Response Evaluation Criteria In Solid Tumors (RECIST) at the first evaluation on computed tomography (CT) was obtained from a multicenter, randomized phase III trial ("TEX trial," n = 287) comparing treatment with a combination of epirubicin and paclitaxel alone or with capecitabine (TEX). Cox regression and Kaplan-Meier analyses were performed to evaluate the correlations between the first change in tumor size, response according to RECIST and OS. Data from CT evaluations of 233 patients were available. Appearance of new lesions or progression of non-target lesions (new/non-target) indicated short OS by univariable regression analysis (HR 3.76, 95 % CI 1.90-7.42, p < 0.001). A decrease by >30 % at this early time point was prognostic favorable (HR 0.69, 95 % CI 0.49-0.98, p = 0.04) and not significantly less than the best overall response according to RECIST. After adjustment for previous adjuvant treatment and the treatment given within the frame of the randomized trial, OS was still significantly shorter in patients with new/non-target lesions after a median 8 weeks of treatment (HR 4.41, 95 % CI 2.74-7.11, p < 0.001). Disease progression at the first evaluation correlates with OS in patients with MBC treated with first-line combination chemotherapy. The main reason for early disease progression was the appearance of new lesions or progression of non-target lesions. These patients had poor OS even though more lines of treatment were available. Thus, these factors should be focused on in the response evaluations besides tumor size changes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322522     DOI: 10.1007/s12032-012-0415-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  On the relationship between response to treatment and survival time.

Authors:  M Buyse; P Piedbois
Journal:  Stat Med       Date:  1996-12-30       Impact factor: 2.373

3.  End points and United States Food and Drug Administration approval of oncology drugs.

Authors:  John R Johnson; Grant Williams; Richard Pazdur
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

4.  Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.

Authors:  T Hatschek; L Carlsson; Z Einbeigi; E Lidbrink; B Linderholm; B Lindh; N Loman; M Malmberg; S Rotstein; M Söderberg; M Sundquist; T M Walz; M Hellström; H Svensson; G Aström; Y Brandberg; J Carstensen; M Fernö; J Bergh
Journal:  Breast Cancer Res Treat       Date:  2011-11-18       Impact factor: 4.872

5.  Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Authors:  Primo N Lara; Mary W Redman; Karen Kelly; Martin J Edelman; Stephen K Williamson; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

6.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

Review 7.  Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

Authors:  Nicholas Wilcken; Rachel Dear
Journal:  Eur J Cancer       Date:  2008-08-20       Impact factor: 9.162

8.  Potential of reduction in total tumor volume measured with 3D-MRI as a prognostic factor for locally-advanced breast cancer patients treated with primary chemotherapy.

Authors:  Kenji Akazawa; Yasuhiro Tamaki; Tetsuya Taguchi; Yoshio Tanji; Yasuo Miyoshi; Seung Jim Kim; Kenzo Shimazu; Satsuki Ueda; Tetsu Yanagisawa; Noritsugu Okishiro; Mitsunobu Imazato; Kozuma Yasuyuki; Yoshinobu Sato; Shinichi Tamura; Shinzaburo Noguchi
Journal:  Breast J       Date:  2008-10-13       Impact factor: 2.431

9.  The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.

Authors:  W Graf; L Påhlman; R Bergström; B Glimelius
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

10.  Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

Authors:  Gunter von Minckwitz; Hans-Peter Sinn; Günter Raab; Sibylle Loibl; Jens-Uwe Blohmer; Holger Eidtmann; Jörn Hilfrich; Elisabeth Merkle; Christian Jackisch; Serban D Costa; Angelika Caputo; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2008-04-01       Impact factor: 6.466

View more
  4 in total

1.  Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.

Authors:  Alexios Matikas; Athanasios Kotsakis; Maria Perraki; Dora Hatzidaki; Konstantinos Kalbakis; Emmanouil Kontopodis; Michail Nikolaou; Vasilios Georgoulias
Journal:  Breast Care (Basel)       Date:  2021-10-29       Impact factor: 2.268

2.  Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.

Authors:  Siao-Nge Hoon; Peter Kh Lau; Alison M White; Max K Bulsara; Patricia D Banks; Andrew D Redfern
Journal:  Cochrane Database Syst Rev       Date:  2021-05-26

3.  Survival Analysis of Breast Cancer Patients after Surgery with an Intermediate Event: Application of Illness-Death Model.

Authors:  Morteza Hajihosseini; Javad Faradmal; Abdolazim Sadighi-Pashaki
Journal:  Iran J Public Health       Date:  2015-12       Impact factor: 1.429

4.  Immune gene expression and response to chemotherapy in advanced breast cancer.

Authors:  Theodoros Foukakis; John Lövrot; Alexios Matikas; Ioannis Zerdes; Julie Lorent; Nick Tobin; Chikako Suzuki; Suzanne Egyházi Brage; Lena Carlsson; Zakaria Einbeigi; Barbro Linderholm; Niklas Loman; Martin Malmberg; Mårten Fernö; Lambert Skoog; Jonas Bergh; Thomas Hatschek
Journal:  Br J Cancer       Date:  2018-01-25       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.